Production (Stage)
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.4121
$0.053114.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 10.00K | 4.00K | 29.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 10.00K | 4.00K | 29.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 10.00K | 4.00K | 29.00K |
| SG&A Expenses | 4.22M | 948.00K | 1.24M | 1.63M | 1.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.04M | 1.83M | 2.19M | 3.65M | 4.38M |
| Operating Income | -5.04M | -1.83M | -2.18M | -3.64M | -4.36M |
| Income Before Tax | -81.00K | -1.86M | -2.17M | -3.67M | -4.30M |
| Income Tax Expenses | -- | 1.19M | -210.00K | -412.00K | -1.35M |
| Earnings from Continuing Operations | -81.00K | -3.05M | -1.96M | -3.26M | -2.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.00K | -3.05M | -1.96M | -3.26M | -2.95M |
| EBIT | -5.04M | -1.83M | -2.18M | -3.64M | -4.36M |
| EBITDA | -5.03M | -1.83M | -2.18M | -3.64M | -4.35M |
| EPS Basic | 0.00 | -5.28 | -14.55 | -28.87 | -2.27 |
| Normalized Basic EPS | -0.02 | -2.01 | -10.07 | -20.32 | -2.07 |
| EPS Diluted | 0.00 | -5.28 | -14.55 | -28.87 | -2.27 |
| Normalized Diluted EPS | -0.02 | -2.01 | -10.07 | -20.32 | -2.07 |
| Average Basic Shares Outstanding | 207.34M | 577.70K | 134.50K | 112.80K | 1.30M |
| Average Diluted Shares Outstanding | 207.34M | 577.70K | 134.50K | 112.80K | 1.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |